2022
The use of intraovarian injection of autologous platelet rich plasma (PRP) in patients with poor ovarian response and premature ovarian insufficiency
Herlihy NS, Seli E. The use of intraovarian injection of autologous platelet rich plasma (PRP) in patients with poor ovarian response and premature ovarian insufficiency. Current Opinion In Obstetrics & Gynecology 2022, 34: 133-137. PMID: 35645011, DOI: 10.1097/gco.0000000000000784.Peer-Reviewed Original ResearchConceptsPoor ovarian responsePlatelet-rich plasmaPrimary ovarian insufficiencyPoor prognosis patientsPrognosis patientsOvarian reserveIntraovarian injectionOvarian responseOvarian insufficiencyLive birthsRich plasmaEffect of PRPAutologous platelet-rich plasmaIntra-ovarian injectionPremature ovarian insufficiencyMultiple live birthsProspective trialCase seriesClinical trialsPatient's abilityNovel treatmentsPatientsEmbryo yieldInsufficiencyTreatment
2004
Treatment of PCOS with metformin and other insulin-sensitizing agents
Seli E, Duleba AJ. Treatment of PCOS with metformin and other insulin-sensitizing agents. Current Diabetes Reports 2004, 4: 69-75. PMID: 14764283, DOI: 10.1007/s11892-004-0014-8.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeInsulin-sensitizing agentsSerum insulinInsulin resistanceTreatment of PCOSType 2 diabetes mellitusElevated serum insulinUse of metforminTreatment of womenOvary syndromeCompensatory hyperinsulinemiaDiabetes mellitusOvulatory functionD-chiro-inositolAndrogen levelsCardiovascular disordersMetforminHyperinsulinemiaWomenSignificant proportionTreatmentInsulinAgentsHyperandrogenismAnovulation
2002
Should patients with polycystic ovarian syndrome be treated with metformin?
Seli E, Duleba AJ. Should patients with polycystic ovarian syndrome be treated with metformin? Human Reproduction 2002, 17: 2230-2236. PMID: 12202407, DOI: 10.1093/humrep/17.9.2230.Peer-Reviewed Original ResearchConceptsPolycystic ovarian syndromeTreatment of PCOSInsulin-lowering agentsOvarian syndromePathogenesis of PCOSType 2 diabetes mellitusPromising therapeutic profileEarly spontaneous miscarriageOral antihyperglycaemic agentsInsulin-sensitizing drugsType 2 diabetesRisk of developmentImportant aetiologic factorPlasminogen activator inhibitorSerum lipidsDiabetes mellitusCardioprotective effectsAetiologic factorsAntihyperglycaemic agentsInsulin resistanceSpontaneous miscarriageMetforminTherapeutic profileActivator inhibitorTreatment